Endocrine Abstracts

Objectives: Amino acids (AA) plasma profile is associated with cardiometabolic diseases (CMD), predicts diabetes mellitus type 2 (DM2) and cardiovascular diseases (CVD) many years in advance. Metabolic syndrome (MS) defines the area of metabolic disturbances that precede DM2 and CVD development. The primary objective of the study was to examine the association between BCAA (branched chain amino acids), AAA (aromatic amino acids) profile and MS’s phenotype and to evaluate its clinical utility for MS diagnosis.

Methods: 263 healthy, professionally active men, with and without MS (MS+, n=165; MS−, n=98) were included into the study. Anthropometrical, biochemical and AA measurements were performed. AA were tested for the ability to discriminate subjects with MS and insulin resistance irrespectively. Based on logistic discrimination multivariate early MS diagnostic model was built and its discrimination properties were evaluated.

Results: 2 functionally independent AA clusters were identified. BCAA and phenylalanine differed strongly between MS+ and MS- participants (p=0.003), appeared as significant indicator of MS+ individuals (AUC 0.66; 95%CI: 0.5757–0.7469) and correlated with cardiometabolic factors. No statistical significant differences in AAs concentrations between IR+ and IR− groups were noted and none of the AA group appeared as meaningful IR+ indicator. Proposed MS multivariate diagnostic model consisted of phenylalanine, insulin, leptin, adiponectin and had good discrimination properties – AUC 0,79; (95% CI: 0.7239–0.8646).

Conclusions: MS is associated with selective hiperaminoacydemia that could be a part of CMD pathogenesis. Present study suggests that AA disturbances do not derive directly from insulin sensitivity impairment nor obesity or muscle mass. AA utility for MS diagnosis needs further evaluation. The original outcome of the study became MS diagnostic model creation – MS screen test, with good discrimination properties and that could be validated in the next coming studies.